Balance Therapeutics

About Balance Therapeutics

Management

Morgan Lam - President

Morgan serves as President and is responsible for leading operations and development of product BTD-001. Previously, he was the Chief Operating Officer and Senior Vice President of Development for Humanigen Inc. (formerly KaloBios Pharmaceuticals, Inc.) from January 2016 to 2018 where he was responsible for the development of lenzilumab and ifabotuzumab for various oncology and non-oncology indications. Prior to that, he served as Executive Director for Medical & Scientific Affairs for Geron Corp. as well as Head of Clinical Operations Department from 2010 to 2015 where he played a key role in the development of imetelstat. Prior to that, Morgan spent six years at Genentech Inc. (now Hoffman LaRoche) as Clinical Program Manager in leading the clinical operations efforts for numerous oncology drug candidates including Gazyva® and Venclexta™ for the treatment for various solid and liquid tumors. Before Genentech, he worked with increasing responsibilities for over six years in the Clinical Development organizations for INEX and QLT Inc.

Morgan received his bachelor’s degree in Microbiology and Biochemistry from the University of British Columbia and currently participates in various executive leadership and entrepreneurship programs.


Alejandro Dorenbaum, M.D. - Head of Clinical Development

Alejandro (Alex) serves as Head of Clinical Development. Previously, he was Chief Medical Officer at Allakos Pharmaceutical where he achieved proof-of-concept in clinical trials for novel therapeutic antibodies targeting inflammatory cells. He served as Chief Medical Officer at Lumena Pharmaceutical until it's acquisition by Shire. Prior to that, Alex joined Genentech, where he was responsible for the respiratory programs for asthma and cystic fibrosis, BioMarin Pharmaceutical, Inc. where he conducted the clinical development of Kuvan® and Chiron Corporation where he acquired broad expertise in several areas of drug development including biologics, small molecules, and vaccines. Alex consults for several early development companies and he maintains an active academic position as Clinical Professor of Pediatrics at Stanford University School of Medicine, where he treats patients with Allergy and Immunology clinical problems.


Xiao-Xiong Lu, Ph.D. - Vice President of Technical Operations

Xiao-Xiong serves as Vice President of Technical Operations responsible for all aspects of pharmaceutical CMC development, manufacturing and supply chain. He has 30 years of experience in the US pharmaceutical and related industries having worked at both large pharma and small to medium biotech companies. He has consulted for a number of biotech and pharmaceutical companies in the areas of CMC and business development. From 2003 to 2015, he was with Arena Pharmaceuticals, most recently as Associate VP of CMC Technical Operations as well as Managing Director for Greater China. From 1990 to 2003, he worked at Monsanto Company and its spin-off Solutia Inc. with increasing responsibilities in R&D and manufacturing. 

Xiao-Xiong received his PhD in Chemical Engineering from University of Birmingham in the UK and has taken MBA courses at Louisiana State University.


Lyndon Lien, Ph.D. - Co-founder & Advisor

Lyndon serves as Advisor and member of the Board of Directors for Balance Therapeutics. Previously he was President, Chief Executive Officer and Co-founder of Balance Therapeutics and provided overall leadership for the company for over 8 years. Lyndon is an Operating Partner with Nan Fung Life Sciences and Pivotal bioVenture Partners where he invests in, manages and builds transformational life sciences companies. Prior to Balance Therapeutics, Lyndon was Vice President of Corporate Strategy and Alliances at Elan Pharmaceuticals and was responsible for strategic planning, product planning and business development. As Director of Technology Planning at ALZA, a specialty pharmaceutical company of Johnson & Johnson, he led technology strategy and guided new product planning teams. He was a Principal at the venture capital company Coastview Capital and led and supported successful investments in early stage biopharmaceutical and research tool companies. He was also a management consultant at McKinsey & Company and a leader in the Pharmaceutical and Medical Products Practice. He provided direction to senior executives of leading healthcare companies on business strategy, R&D strategy, operations, new business creation, mergers/acquisitions, and product commercialization.

Lyndon has an A.B. in Biochemical Sciences from Harvard University, an M.B.A. from MIT Sloan School of Management and a Ph.D. in Genetics from Harvard University.


Management also works closely with a team of consultants and partners across key functions including manufacturing, preclinical toxicology, clinical development, clinical operations, data management, statistics, quality and regulatory affairs.


Board of Directors

Phyllis Whiteley, Ph.D. - Executive Board Chair

Phyllis Whiteley, PhD., is a Venture Partner with Wildcat Venture Partners where she provides hands-on leadership in building, investing, and creating companies in the digital health space. She is also a Venture Partner with Mohr Davidow Ventures where she focused on diagnostics, life science tools, digital health, and personalized medicine including Verinata Health, acquired by Illumina (NASDAQ: ILMN). Dr. Whiteley has built a career around her passion for personalized medicine, global healthcare, and transformative life science innovations. She has founded and built multiple companies in the United States and abroad.

Her executive expertise includes R&D, strategic planning, financing, partnerships, restructuring, building executive teams and M&A. Dr. Whiteley previously co-founded Anaphore, Inc. (now Bird Rock Bio) with 5AM Ventures. Prior to her work in Venture Capital, she was an Officer and Senior Vice President, Business Development, Licensing, and Alliance Management at Perlegen Sciences, Inc. Before joining Perlegen, she served as Vice President, Strategic Portfolio Management for Roche. Over her ten-year career with Roche she held various positions in Business Development based in Basel, Switzerland coupled with R&D leadership positions in the US. Prior to her Roche tenure, Dr. Whiteley held a Senior Research Immunology role with Merck.

Dr. Whiteley, currently serves on multiple boards including Analyte Health (Chair), Carrum Health, Balance Therapeutics (chair), and University of California, San Francisco Leadership Council for Global Health. Dr. Whiteley chairs the advisory board for the University of Texas Horizon Fund and serves as an advisor to the University of Michigan, Science and Innovation, school of nursing. She is also a Global Social Benefit Incubator (GSBI) mentor at Santa Clara University in Santa Clara, California. Dr. Whiteley received her BA in Chemistry and PhD in Pharmacology from Washington University in St. Louis, Missouri.


Peter Carlton, CFA

Peter is Managing Director at Oakmont Corporation, a registered investment advisor formed in 1984 to serve as the family office for the founder of Trust Company of the West and now overseeing approximately $2.5b in assets for high networth clients and investors. His key responsibilities at Oakmont include leading the investment team that manages Oakmont's portfolio of private equity investments. Peter also serves as president of The Cypress Funds, an affiliated long/short hedge fund with $400m of assets under management. He also serves on the board of directors of Liberty Oilfield Services, TruthMD LLC, and Balance Therapeutics. He has over eleven years of experience working in the investment management industry.

Peter is a CFA charter holder and a member of the CFA Society of Los Angeles. Peter holds a BA in Economics from the University of Colorado.


Carl L. Gordon, Ph.D., CFA

Carl is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a Senior Biotechnology Analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995.

Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987). Carl was included on the Forbes Midas List of top venture capital investors in 2014.


Lyndon Lien, Ph.D.

Lyndon is an Operating Partner with Nan Fung Life Sciences and Pivotal bioVenture Partners where he invests in, manages and builds transformational life sciences companies. Previously, he served as President, Chief Executive Officer and Co-Founder of Balance Therapeutics and provided overall leadership for the company for over 8 years. Prior to that, Lyndon was Vice President of Corporate Strategy and Alliances at Elan Pharmaceuticals and was responsible for strategic planning, product planning and business development. As Director of Technology Planning at ALZA, a specialty pharmaceutical company of Johnson & Johnson, he led technology strategy and guided new product planning teams. He was a Principal at the venture capital company Coastview Capital and led and supported successful investments in early stage biopharmaceutical and research tool companies. He was also a management consultant at McKinsey & Company and a leader in the Pharmaceutical and Medical Products Practice. He provided direction to senior executives of leading healthcare companies on business strategy, R&D strategy, operations, new business creation, mergers/acquisitions, and product commercialization.

Lyndon has an A.B. in Biochemical Sciences from Harvard University, an M.B.A. from MIT Sloan School of Management and a Ph.D. in Genetics from Harvard University.


Kyle Rasbach

Kyle joined Pappas Capital in January 2018, bringing with him extensive experience in clinical pharmacology, basic science and healthcare equity research. Prior to joining Pappas, he was an equity research analyst and Vice President at T. Rowe Price in Baltimore, where he managed pharmaceutical, specialty pharmaceutical and biotechnology investments for all T. Rowe Price funds. During his time at T. Rowe, Kyle led the firm's IPO investment in Pappas portfolio company CoLucid Pharmaceuticals (NASDAQ: CLCD), which was eventually sold to Eli Lilly for just under $1 billion. Prior to joining T. Rowe, Kyle was an equity research associate and Vice President at Cowen and Company in Boston, where he covered global pharmaceutical equities. He completed his postdoctoral work in the laboratory of Bruce Spiegelman at Harvard Medical School, where he contributed to a number of high profile publications, including papers in Cell, Cell Metabolism, Nature and PNAS.